AXON Neurosciences Pioneering Tau Vaccine Against Alzheimers Started Phase II

BRATISLAVA, Slovakia–(BUSINESS WIRE)–AXON Neuroscience announced the successful start of the ADAMANT phase II study, as the first patient has been vaccinated with the active tau vaccine. AXON’s vaccine, AADvac1, is intended to be the first disease-modifying tau vaccine for Alzheimer’s disease. “This is an exciting era as we believe that the positive results from the phase I study could soon be confirmed by this phase II study.” ADAMANT PHASE II CLINICAL STUDY ADAMANT is a 24-month, randomized, placebo-controlled, parallel group, double-blinded, multi-centre, phase II study to assess the safety and efficacy of AADvac1 applied to patients with mild Alzheimer’s disease. The primary objective is to confirm the positive phase I results by assessing safety and immunogenicity on a larger patient population with mild Alzheimer’s disease. The secondary objective is to…


Link to Full Article: AXON Neurosciences Pioneering Tau Vaccine Against Alzheimers Started Phase II